- AbbVie to present at ESMO 2026 (Oct 23-27, Madrid).
- Seven assets: Temab-A, ABBV-706, ABBV-969, ABBV-1480, alveltamig, Elahere, Emrelis.
- Temab-A: 30% ORR in CRC (n=30), 50% ORR in EGFR wild-type NSCLC (n=48), 63% in EGFR-mutant NSCLC (n=41).
- Temab-A: FDA Breakthrough Therapy Designations in CRC and NSCLC.
- ABBV-706: 56% ORR in 2L+ SCLC (n=41), 82% in 2L subset (n=17).
- ABBV-969: 90% ctDNA reduction >=50% in mCRPC (n=49).
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card